Study Reveals How Immunogenetics Influence Lung Cancer Risk

Recent research in cancer immunotherapy has emphasized the crucial role of the immune system in combating cancer. Now, a new study led by researchers from the Icahn School of Medicine at Mount Sinai has unveiled how variations in immune genetics impact lung cancer risk.

Published in Science, the study focused on human leukocyte antigen (HLA) molecules, essential for immune recognition. The study discovered that individuals with heterozygosity at HLA-II genes exhibited a reduced risk of lung cancer, particularly significant among smokers. This challenges traditional beliefs and underscores the importance of immune genetics in cancer susceptibility. By incorporating polygenic risk scores into their analysis, the team identified an increased lifetime risk of lung cancer in smokers with identical versions of HLA-II genes.

This research not only improves our understanding of lung cancer but also could improve cancer risk assessment by highlighting the role of the immune system alongside inherited and environmental factors. The findings pave the way for more targeted prevention strategies harnessing the immune system to combat cancer effectively.

Moving forward, the team plans to delve deeper into understanding the protective effects of HLA heterozygosity and explore non-classical CD4 T cells and HLA class II in cancer biology. This study marks a significant step toward unraveling the intricate relationship between the immune system and cancer risk, offering hope for more precise screening, prevention, and treatment approaches in the future.